Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Editorial

The Novel Use of Lipids as Diagnostic Tools and Therapeutics in Cancer: Recent Insights and Challenges

Author(s): Chandi C. Mandal

Volume 23, Issue 6, 2022

Published on: 25 April, 2022

Page: [542 - 543] Pages: 2

DOI: 10.2174/138945012306220425130109

[1]
Ortega Moreno L, Navarro Sánchez P, Abalo R. Lipidomics As Tools For Finding Biomarkers Of Intestinal Pathology: From Irritable Bowel Syndrome To Colorectal Cancer. Current drug targets 2021.
[2]
Yarla N, Madka V, Rao C. Targeting triglyceride metabolism for colorectal cancer prevention and therapy. Current drug targets 2021.
[3]
Monchusi B, Kaur M. miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to overcome Drug Resistance in Cancer. Current drug targets 2021.
[4]
Majchrzak K, Piotrowska M, Krajewska J, Fichna J. Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers. Current drug targets 2021.
[5]
Vishwakarma S, Arya N, Kumar A. Regulation of tumor immune microenvironment by sphingolipids and lysophosphatidic acid. Current drug targets 2021.
[6]
Srivastava A, Srivastava P, Mathur S, Abbas S, Rai N, Tiwari S, et al. Lipid metabolism and mitochondria: Cross talk in cancer. Current drug targets 2021.
[7]
Soni S, Torvund M, Mandal C. Omega-3 fatty acid treatment combined with chemotherapy to prevent toxicity, drug resistance, and metastasis in cancer. Current drug targets 2021.
[8]
Chaurawal N, Misra C, Raza K. Lipid-based Nanocarriers loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges. Current drug targets 2021.

© 2024 Bentham Science Publishers | Privacy Policy